EN

TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (TWO.6838) and Aimmax Therapeutics, Inc. (United States) announced that results from a Phase 2 clinical study of APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), a novel formulation of the potent corticosteroid, clobetasol propionate, for the treatment of inflammation and pain after cataract surgery, will be presented at the 2022 Association for …

Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting Read More »

(Corticosteroid for inflammation and pain after cataract surgery) TAIPEI – June 3, 2021 – Formosa Pharmaceuticals (“Formosa”, stock code:6838) and China Grand Pharma (“Grand”, HKG stock code:00512) announce that they have entered into an exclusive licensing agreement for the development and commercialization of Formosa’s APP13007 in the territory defined by Mainland China, Hong Kong, and …

Formosa Pharmaceuticals and China Grand Pharmaceutical and Healthcare Holdings Limited enter into licensing agreement for APP13007 Read More »

April 16, 2021 Formosa Pharmaceuticals (FP), a subsidiary of Formosa Laboratories (TWSE 4746), has successfully completed a Series C financing round, increasing its cash capital by NTD $600 million (approx. USD $21.1 million). In addition to the continuous support from major shareholder, Formosa Laboratories, numerous prominent venture capital firms participated in this round of capital …

Formosa Pharmaceuticals completes USD $21.1 million fundraising and increase in cash capital Read More »

Formosa Pharmaceuticals and AimMax Therapeutics report top-line results from a Phase 2 clinical trial of APP13007 for the treatment of inflammation and pain after cataract surgery. The End-of-Phase 2 meeting with the FDA is successful, setting the stage for pivotal Phase 3 trials to begin as early as 2020-Q4. APP13007 meets primary endpoints demonstrating rapid …

APP13007 completes Phase 2 clinical trial and EOP2 meeting. Read More »